Search Within

Alison Moskowitz

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (31)
  2. Journal Article (24)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (56)
  2. Center for Hematologic Malignancies (56)
  3. Department of Medicine (56)
  4. Epidemiology and Biostatistics (56)
  5. Hematologic Malignancies, Division of (56)
  6. Lymphoma (56)

More Groups

People
  1. Steven Horwitz (43)
  2. Matthew Matasar (40)
  3. Andrew Zelenetz (39)
  4. Anas Younes (36)
  5. Anita Kumar (35)
  6. David Straus (35)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (4)
  6. 2020 (9)

More Years

Publications
  1. Blood (20)
  2. Hematological Oncology (8)
  3. Blood Advances (5)
  4. Blood Cancer Journal (5)
  5. British Journal of Haematology (3)
  6. Biology of Blood and Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. Wiley Blackwell (8)
  3. Elsevier Inc. (5)
  4. Nature Publishing Group (5)
  5. American Association for Cancer Research (4)
  6. John Wiley & Sons (3)

More Publishers

Results (56)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A prospective study of allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Perales, M. A.; Cho, C.; Eaton, A.; Moskowitz, A. J.; Nguyen, V.; Gonzales-Dadiz, A. M. R.; Devlin, S.; Giralt, S. A.; Jakubowski, A. A.; Matasar, M. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging: Research paper
    Journal Article

    Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Zhang, Z.; Filippa, D.; Teruya-Feldstein, J.; Kewalramani, T.; Moskowitz, A. J.; Rice, R.; Maragulia, J.; more...
    British Journal of Haematology (2010)

    Fulltext@MSK | Save
  • Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Perales, M. A.; Kewalramani, T.; Yahalom, J.; Castro-Malaspina, H.; Zhang, Z.; Vanak, J.; Zelenetz, A. D.; Moskowitz, C. H.
    British Journal of Haematology (2009)

    Fulltext@MSK | Save